EDUCATION

Medical School

  • Dartmouth Medical School , 2012 , Hanover , NH

Residency

  • Boston Children's Hospital/Boston Medical Center , 2015 , Boston , MA

Fellowship

  • Dana-Farber Cancer Institute/Boston Children's Hospital , 2018 , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, General Pediatrics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Liu KX, Collins NB, Greenzang KA, Furutani E, Campbell K, Groves A, Mullen EA, Shusterman S, Spidle J, Marcus KJ, Weil BR, Weldon CB, Frazier AL, Janeway KA, O'Neill AF, Mack JW, DuBois SG, Shulman DS. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 Jul 19; e28559. View abstract
  2. Furutani E, Shah AS, Zhao Y, Andorsky D, Dedeoglu F, Geddis A, Zhou Y, Libermann TA, Myers KC, Shimamura A. Inflammatory manifestations in patients with Shwachman-Diamond syndrome: A novel phenotype. Am J Med Genet A. 2020 07; 182(7):1754-1760. View abstract
  3. Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, Alosaimi MF, Stafstrom K, Platt CD, Stauber T, Raz S, Tirosh I, Weiss A, Jordan MB, Krupski C, Eleftheriou D, Brogan P, Sobh A, Baz Z, Lefranc G, Irani C, Kilic SS, El-Owaidy R, Lokeshwar MR, Pimpale P, Khubchandani R, Chambers EP, Chou J, Geha RS, Nigrovic PA, Zhou Q. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020 Jun; 145(6):1664-1672.e10. View abstract
  4. Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020 Mar; 7(3):e238-e246. View abstract
  5. Furutani E, Shimamura A. Genetic predisposition to MDS: diagnosis and management. Hematology Am Soc Hematol Educ Program. 2019 12 06; 2019(1):110-119. View abstract
  6. Schoettler M, Duncan C, Lehmann L, Furutani E, Subramaniam M, Margossian S. Ruxolitinib is an effective steroid sparing agent in children with steroid refractory/dependent bronchiolitis obliterans syndrome after allogenic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 07; 54(7):1158-1160. View abstract
  7. Furutani E, Newburger PE, Shimamura A. Neutropenia in the age of genetic testing: Advances and challenges. Am J Hematol. 2019 03; 94(3):384-393. View abstract
  8. Gansner JM, Furutani E, Campagna DR, Fleming MD, Shimamura A. Pancreatic lipomatosis in Diamond-Blackfan anemia: The importance of genetic testing in bone marrow failure disorders. Am J Hematol. 2018 09; 93(9):1194-1195. View abstract
  9. Furutani E, Rodriguez-Galindo C, Green AL. Early death in pediatric cancer: remaining questions and next steps. Oncotarget. 2017 Nov 14; 8(57):96478-96479. View abstract
  10. Green AL, Furutani E, Ribeiro KB, Rodriguez Galindo C. Death Within 1 Month of Diagnosis in Childhood Cancer: An Analysis of Risk Factors and Scope of the Problem. J Clin Oncol. 2017 Apr 20; 35(12):1320-1327. View abstract
  11. Furutani E, Shimamura A. Germline Genetic Predisposition to Hematologic Malignancy. J Clin Oncol. 2017 Mar 20; 35(9):1018-1028. View abstract
  12. Stredny CM, Frosch O, Singhi S, Furutani E, Durbin AD, Grace RF, Ullrich NJ. Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatr Neurol. 2016 09; 62:66-70. View abstract
  13. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS, Furutani E, Perez-Sanz TM, Graveline A, Janssens SP, Picard MH, Scherrer-Crosbie M, Bloch KD. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation. 2007 Jul 31; 116(5):506-14. View abstract
  14. Ichinose F, Buys ES, Neilan TG, Furutani EM, Morgan JG, Jassal DS, Graveline AR, Searles RJ, Lim CC, Kaneki M, Picard MH, Scherrer-Crosbie M, Janssens S, Liao R, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock. Circ Res. 2007 Jan 05; 100(1):130-9. View abstract
  15. Hataishi R, Rodrigues AC, Neilan TG, Morgan JG, Buys E, Shiva S, Tambouret R, Jassal DS, Raher MJ, Furutani E, Ichinose F, Gladwin MT, Rosenzweig A, Zapol WM, Picard MH, Bloch KD, Scherrer-Crosbie M. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006 Jul; 291(1):H379-84. View abstract